1. Home
  2. WFF vs NEUP Comparison

WFF vs NEUP Comparison

Compare WFF & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WF Holding Limited Ordinary Shares

WFF

WF Holding Limited Ordinary Shares

HOLD

Current Price

$0.43

Market Cap

11.1M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.06

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WFF
NEUP
Founded
1984
1996
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
10.3M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
WFF
NEUP
Price
$0.43
$4.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
202.8K
75.6K
Earning Date
12-31-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,021,079.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.45
N/A
52 Week Low
$0.41
$3.00
52 Week High
$29.26
$21.40

Technical Indicators

Market Signals
Indicator
WFF
NEUP
Relative Strength Index (RSI) 44.91 45.13
Support Level $0.43 $3.82
Resistance Level $0.51 $4.00
Average True Range (ATR) 0.08 0.19
MACD -0.00 0.11
Stochastic Oscillator 10.07 49.36

Price Performance

Historical Comparison
WFF
NEUP

About WFF WF Holding Limited Ordinary Shares

WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: